CJC-1295 (without DAC) 5mg + Ipamorelin 5mg

This blend combines CJC-1295 without DAC (often described as Mod GRF 1-29) with Ipamorelin. CJC-1295 without DAC acts through the GHRH receptor pathway, while Ipamorelin is a selective GHS-R1a agonist. Research uses the pairing to examine complementary signalling involved in pulsatile pituitary growth-hormone release.Research-use reference: This description is mechanistic and informational only. It does not provide a protocol, dose or therapeutic recommendation.